Chemical Characterization Under ISO 10993-18:2020 – What Device Makers Get Wrong

iso-10993-18-chemical-characterization-medical-devices
ISO 10993-18:2020 Chemical Characterization Extractables & Leachables Toxicological Risk Assessment Medical Device Safety
Chemical Characterization Under ISO 10993-18:2020 — What Device Makers Get Wrong
CHEMICAL CHARACTERIZATION

Chemical Characterization
Under ISO 10993-18:2020
— What Device Makers
Get Wrong

Incomplete strategies, poor study design and inadequate risk assessments are the most common reasons chemical characterization fails to satisfy modern regulators.


Chemical characterization has become one of the most important components of modern medical device safety evaluation. Under ISO 10993-18:2020, regulators now expect manufacturers to generate detailed scientific evidence regarding the chemical composition, extractables, leachables and toxicological risks associated with medical device materials.

However, many device manufacturers still underestimate the complexity of chemical characterization studies. As regulatory expectations continue to evolve, incomplete strategies, poor study design and inadequate risk assessments are becoming common reasons for approval delays and regulatory deficiencies.

At Accuprec Research Labs Pvt. Ltd., we help medical device manufacturers develop scientifically robust and regulator-ready chemical characterization programs aligned with ISO 10993-18:2020 and global regulatory expectations.


THE FOUNDATION

Why Chemical Characterization Is Critical

Chemical characterization provides essential information about the materials used in medical devices and identifies compounds that may migrate from the device during clinical use. Modern regulators increasingly rely on chemical characterization because it provides a scientific foundation for understanding device-material interactions and potential patient exposure risks.

Without comprehensive chemical characterization data, manufacturers may face significant challenges during regulatory review.

These studies support:

  • Biological safety evaluation
  • Toxicological risk assessment
  • Material qualification
  • Regulatory compliance
  • Biocompatibility planning
  • Patient safety assurance

WHAT GOES WRONG

Common Mistakes Device Makers Make

One of the biggest mistakes manufacturers make is treating chemical characterization as a routine analytical activity instead of a strategic regulatory requirement.

  • Incomplete extractables and leachables studies
  • Poorly defined analytical thresholds
  • Inadequate method sensitivity
  • Weak toxicological assessments
  • Insufficient material information
  • Lack of regulatory-focused study planning
  • Failure to align with ISO 10993-18:2020 expectations

In many cases, companies generate analytical data without a clear toxicological interpretation strategy — which leads to regulator concerns and additional information requests.


CORE REQUIREMENT

The Importance of Extractables & Leachables Studies

Extractables and leachables evaluations are central to chemical characterization programs.

Extractables

Extractables Studies

Identify chemicals that can potentially migrate from device materials under aggressive laboratory extraction conditions — simulating worst-case scenarios.

Leachables

Leachables Studies

Assess compounds actually released during real clinical use conditions — representing genuine patient exposure scenarios.

These evaluations help determine:

  • Patient exposure risks
  • Material compatibility
  • Toxicological safety margins
  • Manufacturing consistency
  • Long-term device safety

Without properly designed extractables and leachables studies, manufacturers may fail to adequately characterize device-related risks.


ANALYTICAL EXCELLENCE

Advanced Analytical Capabilities Matter

Reliable chemical characterization requires highly sensitive and scientifically validated analytical technologies. At Accuprec, our scientific teams also ensure that analytical methods are appropriately validated and aligned with regulatory expectations.

Our laboratories support advanced characterization studies using:

GC-MS Analysis

Gas chromatography-mass spectrometry for volatile and semi-volatile organic compound identification and quantification.

LC-MS/MS Analysis

Liquid chromatography tandem mass spectrometry for non-volatile and trace-level compound detection with high sensitivity.

ICP-MS Analysis

Inductively coupled plasma mass spectrometry for ultra-trace elemental impurity and metal leachables analysis.

Spectroscopic Analysis

FTIR, UV-Vis and Raman spectroscopy for structural identification and material characterization support.

Chromatographic Profiling

Comprehensive organic and inorganic compound profiling for complete chemical characterization packages.


BEYOND ANALYTICS

Regulatory-Focused Risk Assessment

Generating analytical data alone is not sufficient. Modern regulators expect manufacturers to provide toxicological interpretation and scientifically justified risk assessments. This integrated approach strengthens regulatory submissions and improves reviewer confidence.

At Accuprec, we help clients develop:

Toxicological Risk Evaluations

Scientific assessment of identified chemical compounds against established toxicological safety thresholds.

Safety Threshold & Exposure Calculations

Quantitative patient exposure assessments with margin of safety calculations per ISO 10993-17.

Regulatory Justification Reports

Scientifically written documentation addressing regulator expectations and supporting approval submissions.

Material Safety Evaluations

Comprehensive device material qualification reports supporting biological evaluation strategies.


THE UPDATED STANDARD

Why ISO 10993-18:2020 Requires a Strategic Approach

The updated ISO 10993-18:2020 standard emphasizes risk-based evaluation and deeper scientific understanding of device materials. Companies that fail to adopt a strategic and scientifically justified approach often encounter regulatory delays and increased approval risks.

Manufacturers are now expected to:

Understand Material Composition

Thoroughly document and evaluate all materials, components and processing aids used in device manufacturing.

Characterize E&L Compounds

Identify and quantify all extractable and leachable compounds using orthogonal analytical techniques.

Establish Analytical Thresholds

Define scientifically justified analytical evaluation thresholds (AET) for identification and reporting.

Integrate Into Biological Evaluation

Connect chemical characterization data directly into the biological evaluation and risk assessment strategy.


WHY ACCUPREC

Why Choose Accuprec?

At Accuprec Research Labs Pvt. Ltd., we provide comprehensive chemical characterization solutions designed to support modern medical device regulatory requirements. We help manufacturers transform complex analytical data into strong regulatory evidence.

  • Advanced analytical instrumentation
  • ISO 10993-focused expertise
  • Regulatory-compliant study execution
  • Toxicological risk assessment support
  • Experienced scientific professionals
  • Reproducible and reliable data generation
  • Audit-ready documentation

CONCLUSION

A Critical Regulatory Expectation, Not Just an Analytical Task

Chemical characterization under ISO 10993-18:2020 is no longer a simple analytical requirement — it is a critical regulatory expectation that directly impacts medical device approval success. Manufacturers must adopt scientifically robust, risk-based and compliance-focused characterization strategies to meet evolving global standards.

With advanced analytical capabilities, toxicological expertise and regulatory-focused scientific support, Accuprec Research Labs Pvt. Ltd. helps device manufacturers generate reliable chemical characterization data with confidence.


Partner with Accuprec Research Labs Pvt. Ltd.

Comprehensive ISO 10993-18:2020 compliant chemical characterization solutions for medical device manufacturers worldwide.

Ahmedabad, Gujarat, India +91 99099 19545 info@accuprec.com
What do you think?
Leave a Reply

Your email address will not be published. Required fields are marked *

Insights

More Related Articles

One Implant. Seven Evaluations. How ISO 10993 Biological Testing Works End-to-End

What Makes a Biocompatibility Testing Partner Truly Reliable in 2026?

From CDSCO to FDA to CE Mark: Building One Testing Strategy That Satisfies Multiple Regulators